SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that Tamara Seymour, Chief Financial Officer, and David Guy, Chief Commercial Officer, will present at two upcoming investor conferences:
-- AG Edwards Emerging Growth Conference at 1:00 p.m. Eastern time on Tuesday, September 18, 2007, from the New York Palace Hotel in New York City; and -- Wall Street Analyst Forum at 9:10 a.m. Eastern time on Thursday, September 20, 2007, from the Princeton Club in New York City.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)
Live webcasts of both presentations can be accessed at http://www.favrille.com. Replays will be available approximately one hour after each presentation and archived for one month.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company’s lead product candidate, FavId, is based upon unique genetic information extracted from a patient’s tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFavrille, Inc.
CONTACT: Pete De Spain, Director, Investor Relations & CorporateCommunications of Favrille, Inc., +1-858-526-2426, pdespain@favrille.com
Web site: http://www.favrille.com/
